Papers - INANO AKIHIRO
-
抗がん剤の臨床開発における健康人対象試験の実施状況について
添田 義行, 今井 康人, 飯島 肇, 稲野 彰洋
臨床医薬 32 ( 9 ) 761 - 766 2016.9（ ISSN:0910-8211 ）
-
Yamashita S, Kataoka M, Suzaki Y, Imai H, Morimoto T, Ohashi K, Inano A, Togashi K, Mutaguchi K, Sugiyama Y
Journal of pharmaceutical sciences 104 ( 9 ) 3154 - 61 2015.9（ ISSN:0022-3549 ）
-
【治験や承認基準を知ってこそ薬の適正使用が推進できる!】 活躍する薬剤師 治験マネジメントの実際
稲野 彰洋
薬事 55 ( 5 ) 776 - 781 2013.5（ ISSN:0016-5980 ）
-
Dosing time-dependent influence of raloxifene on plasma plasminogen activator inhibitor-1 concentration in postmenopausal women with osteoporosis
Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, Ushijima K, Hosohata K, Matsushita E, Saito T, Kaneko S, Fujimura A
Clin Exp Pharmacol Physiol. 40 ( 3 ) 227 - 32 2013.3
-
Dosing time-dependent influence of raloxifene on plasma plasminogen activator inhibitor-1 concentration in postmenopausal women with osteoporosis
Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, Ushijima K, Hosohata K, Matsushita E, Saito T, Kaneko S, Fujimura A
Clin Exp Pharmacol Physiol. 40 ( 3 ) 227 - 32 2013.3
-
Dosing time-dependent influence of raloxifene on plasma plasminogen activator inhibitor-1 concentration in postmenopausal women with osteoporosis
Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, Ushijima K, Hosohata K, Matsushita E, Saito T, Kaneko S, Fujimura A
Clin Exp Pharmacol Physiol. 40 ( 3 ) 227 - 32 2013.3
-
Dosing time-dependent influence of raloxifene on plasma plasminogen activator inhibitor-1 concentration in postmenopausal women with osteoporosis
Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, Ushijima K, Hosohata K, Matsushita E, Saito T, Kaneko S, Fujimura A
Clin Exp Pharmacol Physiol. 40 ( 3 ) 227 - 32 2013.3
-
Suzaki Y., Uemura N., Takada M., Ohyama T., Itohda A., Morimoto T., Imai H., Hamasaki H., Inano A., Hosokawa M., Tateishi M., Ohashi K.
European Journal of Clinical Pharmacology 69 ( 1 ) 21 - 30 2013.1（ ISSN:00316970 ）
-
The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano A, Hosokawa M, Tateishi M, Ohashi K.
Eur J Clin Pharmacol 69 ( 1 ) 21 - 30 2013.1
-
The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano A, Hosokawa M, Tateishi M, Ohashi K.
Eur J Clin Pharmacol 69 ( 1 ) 21 - 30 2013.1
-
The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano A, Hosokawa M, Tateishi M, Ohashi K.
Eur J Clin Pharmacol 69 ( 1 ) 21 - 30 2013.1
-
The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano A, Hosokawa M, Tateishi M, Ohashi K.
Eur J Clin Pharmacol 69 ( 1 ) 21 - 30 2013.1
-
非心原性脳梗塞急性期患者を対象としたエダラボン点滴静注液30mg「日医工」、「NS」の有効性と安全性を検討する臨床研究
東原史典, 稲野彰洋, 杉光牧, 外尾加奈, 井林雪郎, 天本敏昭
臨床医薬 28 ( 7 ) 635 - 644 2012.7
-
Pharmacokinetic interaction study of sulfasalazine in health subjects and the impact of curcumin as an in vivo inhibitor of BCRP
Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y.
Br J Pharmacol 2012.2
-
Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
Morimoto K, Kishimura K, Nagami T, Kodama N, Ogama Y, Yokoyama M, Toda S, Chiyoda T, Shimada R, Inano A, Kano T, Tamai I, Ogihara T.
J Pharm Sci 2011.9
-
ラロキシフェンを用いた閉経後骨粗鬆症の時間治療
安藤仁、乙田敏城、永井幸広、西村泰行、稲野彰洋、牛島健太郎、篁俊成、斎藤鉄男、金子周一、藤村昭夫
臨床薬理の進歩 2011.6